Total voting rights
03 Septembre 2018 - 11:12AM
Summit Therapeutics plc (‘the Company’)
Total voting rights
Oxford, UK, and Cambridge, MA, US 3 September 2018
– Summit Therapeutics plc (AIM:SUMM, NASDAQ:SMMT),
announces that in accordance with the FCA's Disclosure and
Transparency Rule 5.6.1, the Company's issued share capital as at
the close of business on 31 August 2018 consisted of 82,125,995
ordinary shares of 1 pence each (‘Ordinary Shares’). There are no
Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in Summit
Therapeutics plc at the date of this notice is 82,125,995.
The above figure of 82,125,995 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure and
Transparency Rules.
-END-
About Summit Therapeutics Summit is a
biopharmaceutical company focused on the discovery, development and
commercialisation of novel medicines for indications for which
there are no existing or only inadequate therapies. Summit is
conducting clinical programs focused on the genetic disease
Duchenne muscular dystrophy and the infectious disease C.
difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
Summit |
|
|
Glyn
Edwards / Richard Pye (UK office) |
Tel: |
44
(0)1235 443 951 |
Erik
Ostrowski / Michelle Avery (US office) |
|
+1
617 225 4455 |
|
|
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: |
+44
(0)20 7213 0880 |
Liam
Murray / Tony Rawlinson |
|
|
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024